ICH E6 (R3) Guideline on good clinical practice (GCP)

International Conference on Harmonisation of technical requirements for registration of pharmaceuticals for human use

GOOD CLINICAL PRACTICE (GCP) E6(R3) Step 5

23 January 2025. Date for coming into effect 23 July 2025

ICH E6(R3) introduces innovative provisions designed to apply across various types and settings of clinical trials, ensuring continued relevance in the face of ongoing technological and methodological advancements. This guideline provides a new language to facilitate innovations in clinical trial design, technology, and operational approaches. It encourages a risk-based and proportionate approach to conducting clinical trials, promoting fit-for-purpose solutions. It fosters transparency through clinical trial registration and result reporting and offers additional guidance to enhance the informed consent process.​

The overarching principles and Annex 1, adopted by ICH and CHMP, came into effect on 23 July 2025.

With the public consultation now concluded, the Annex 2 is expected to be finalised later in 2025.

 

TABLE OF CONTENTS

I. INTRODUCTION 
II. PRINCIPLES OF ICH GCP
III.  ANNEX 1
1. INSTITUTIONAL REVIEW BOARD/INDEPENDENT ETHICS COMMITTEE (IRB/IEC) 
2.  INVESTIGATOR 
3. SPONSOR 
4. DATA GOVERNANCE – INVESTIGATOR AND SPONSOR
Appendix A. INVESTIGATOR’S BROCHURE
Appendix B. CLINICAL TRIAL PROTOCOL AND PROTOCOL AMENDMENT(S)
Appendix C. ESSENTIAL RECORDS FOR THE CONDUCT OF A CLINICAL TRIAL
GLOSSARY

 

© European Medicines Agency, 2025. Reproduction is authorised provided the source is acknowledged.

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000

Clinical Research News

One Shot for Osteoarthritis? Scientists Report Joint Repair in Animals Within Weeks
Pfizer to Test New Pneumococcal Vaccine for Children Needing Catch-up Immunization
Tuberculosis Treatment Is a Long Marathon. A New Trial Will Test if It Can Be Shortened to 17 Weeks
After a Type 1 Diabetes Diagnosis, the Race Against Time Begins. A New Trial Aims to Save Natural Insulin Production
How Low Should "Bad" Cholesterol Go? Trial Tests New Target for Highest-Risk Patients
DYNE-251 to Be Assessed in Phase 3 Trial in Patients with Duchenne Muscular Dystrophy
Oral GLP-1 to Be Tested in People with Type 2 Diabetes Fasting During Ramadan

Upcoming Clinical Trials

Clinical Research Jobs

More jobs

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe